Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VBI Vaccines, Inc. - Ordinary Shares (NQ:VBIV)

0.0653 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about VBI Vaccines, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021
From VBI Vaccines Inc.
Via Business Wire
Why Agenus Stock Is Jumping Today
There was some positive news, but it probably wasn't a huge catalyst for the stock. 
Via The Motley Fool
VBI Vaccines' Brain Cancer Immunotherapy Gets FDA Fast Track Review; Announces Updated Tumor Response, Overall Survival Data
The FDA has granted Fast Track Designation for VBI Vaccines Inc's (NASDAQ: VBIV) VBI-1901, its cancer vaccine immunotherapeutic candidate to treat... 
Via Benzinga
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
From VBI Vaccines Inc.
Via Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
4 Biotech Stocks Wall Street Analysts Predict Will Gain More Than 60%
The integration of technology and successful clinical trials for treating critical ailments have boosted Wall Street’s optimism about several biotech stocks. Analysts expect Bionano, Cerus, Agenus and... 
Via Talk Markets
VBI Vaccines Secures $12M In Second Tranche of Debt Financing With K2 HealthVentures
VBI Vaccines Inc (NASDAQ: VBIV) has announced an agreement to draw down a $12 million second tranche under its previously announced debt financing facility with K2... 
Via Benzinga
VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious Diseases
VBI Vaccines Inc (NASDAQ: VBIV) has announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate... 
Via Benzinga
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in National Securities Corporation’s Biotech Investor Summit
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Presentation at the 2021 Annual Conference on Vaccinology Research
From VBI Vaccines Inc.
Via Business Wire
Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study
Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient... 
Via Benzinga
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
From Brii Biosciences and Vir Biotechnology, Inc. and VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
From VBI Vaccines Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.